Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effects of Combination Therapy With an α1-blocker (Sustained-release Preparation of Bunazosin or Doxazosin) in Inadequate Responders to an Angiotensin II Antagonist (Valsartan) in the Treatment of Patients With Mild to Moderate Essential Hypertension

NCT00130156 is registered in ClinicalTrials.gov with Eisai Inc. as lead sponsor.

NCT NCT00130156
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00130156 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effects of Combination Therapy With an α1-blocker (Sustained-release Preparation of Bunazosin or Doxazosin) in Inadequate Responders to an Angiotensin II Antagonist (Valsartan) in the Treatment of Patients With Mild to Moderate Essential Hypertension
Lead sponsor
Eisai Inc.
Phase
Phase 4
Overall status
Completed
Start date
October 31, 2005
Completion date
March 31, 2009
Enrollment
93 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

high blood pressure